Systematic Financial Management LP Has $19.44 Million Stake in Supernus Pharmaceuticals, Inc. $SUPN

Systematic Financial Management LP raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 23.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 376,079 shares of the specialty pharmaceutical company’s stock after purchasing an additional 71,853 shares during the quarter. Systematic Financial Management LP’s holdings in Supernus Pharmaceuticals were worth $19,440,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Sit Investment Associates Inc. grew its position in Supernus Pharmaceuticals by 0.4% during the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after buying an additional 250 shares in the last quarter. Summit Global Investments increased its stake in Supernus Pharmaceuticals by 6.1% during the first quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 256 shares during the period. Maryland State Retirement & Pension System raised its holdings in Supernus Pharmaceuticals by 3.6% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares in the last quarter. SummitTX Capital L.P. raised its holdings in Supernus Pharmaceuticals by 2.7% in the 4th quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after acquiring an additional 303 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Supernus Pharmaceuticals by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock worth $752,000 after acquiring an additional 321 shares during the period.

Supernus Pharmaceuticals Trading Up 0.5%

NASDAQ SUPN opened at $47.19 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $32.51 and a 1-year high of $59.68. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -92.53, a PEG ratio of 1.00 and a beta of 0.54. The stock’s 50 day moving average is $46.55 and its two-hundred day moving average is $49.27.

Analyst Ratings Changes

Several analysts have recently weighed in on SUPN shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.